StemCellPatents.com Newsletter

Hello manoj kumar valluru,

There has been some recent developments at International Stem Cell Corporation (Video) that we feel you should be aware of.  These recent developments indicate significant progress within the stem cell community and bringing stem cell therapies within reach.

Below, you'll find our official release.

Thanks again for your help in supporting StemCellPatents.com.

StemCellPatents.com Applauds International Stem Cell Corporation (ISCO) On Recent Developments

ISCO First To Grow Human Corneal Tissue From Stem Cells, Entering Pre-Clinical Trials For Retinal Disease & Improved Forms of Corrective Laser Eye Surgery

January 30, 2009--StemCellPatents.com, an organization that covers recent news in stem cell therapeutics and has assembled the only comprehensive index of all issued U.S. stem cell patents, congratulates International Stem Cell Corporation (OTCBB: ISCO), on its recent developments, including being the first company to grow human corneal tissue from stem cells.

ISCO, the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, recently created layered human tissue from its parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa. In related news, ISCO is planning pre-clinical trials aimed at applying corneal epithelial cells grown from human tissue to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery.

Read the rest on StemCellPatents.com.

(BETA)